Fig. 4

HCK is required for AML maintenance. (a) Experimental scheme for investigating the function of HCK in AML maintenance. (b) PCR-based confirmation of HCK deletion in MLL-AF9 leukaemia cells following tamoxifen delivery in vivo. (c) Frequency of YFP⁺ leukaemia cells in the peripheral blood at the indicated time after the second transplantation (n = 10). (d) Representative images of the sizes of spleens of recipient mice. (e) Quantification of the weights of the spleens in d. (f) Histological H&E staining of the spleens in d. (g-h) Representative images and number of colonies formed by YFP⁺c-Kit⁺ LSCs from the secondary recipients. (i) Survival data upon the secondary recipient mice (n = 10; log-rank test). (j) Representative FACS plot and graph of c-Kit and Gr1 expression in HCK^−/− and HCK^+/+ MLL-AF9 leukaemic cells to assess the frequency of LSCs. (k) Representative flow cytometric analysis of the cell cycle distribution in HCK^−/− and HCK^+/+ leukaemic cells from the second transplant recipient in vitro